PDCD1 and lung carcinoma: In our study, data across multiple types of cancer were collected and integrated because previous literature have not reported a large difference in the prevalence of ICI-related pneumonitis in anti-PD-1/PD-L1 antibody monotherapy across lung cancer and non-lung cancer malignancies.14